ImmunityBio‘s patent covers a recombinant SARS-CoV2 vaccine with cross-reactivity against various coronaviruses. The method involves administering the vaccine to elicit an immune response in subjects, targeting different variants of SARS-CoV2. GlobalData’s report on ImmunityBio gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights ImmunityBio Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on ImmunityBio, was a key innovation area identified from patents. ImmunityBio's grant share as of February 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

Cross-reactive sars-cov2 vaccine composition for multiple coronaviruses